VS-041 is currently being evaluated in a phase 1c trial in adult patients with heart failure with preserved ejection fraction and elevated serum levels of endotrophin. The Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback